Protease-Activated Receptor-2 Up-Regulates Transient Receptor Potential Vanilloid 4 Function in Mouse Esophageal Keratinocyte

Digestive Diseases and Sciences

Volumn 60, Issue 12, 2015, Pages 3570-3578

  Suzuki, Nobuhiro ^a   Mihara, Hiroshi ^a   Nishizono, Hirofumi ^a   Tominaga, Makoto ^b   Sugiyama, Toshiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

Author keywords

ATP; GERD; Protease activated receptor 2; Transient receptor potential vanilloid 4

Indexed keywords

DIACYLGLYCEROL; PHOSPHOLIPASE C; PROTEIN KINASE C; PROTEINASE ACTIVATED RECEPTOR 2; VANILLOID RECEPTOR 4; MESSENGER RNA; TRPV4 PROTEIN, MOUSE; VANILLOID RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ESOPHAGUS; ESOPHAGUS BIOPSY; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; KERATINOCYTE; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOPSY; C57BL MOUSE; CELL CULTURE; CYTOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; BIOPSY; CELLS, CULTURED; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; KERATINOCYTES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, PAR-2; RNA, MESSENGER; TRPV CATION CHANNELS; UP-REGULATION;

EID: 84946496172     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3822-6     Document Type: Article

References (38)

1. Kinoshita Y, Adachi K, Hongo M, et al. Systematic review of the epidemiology of gastroesophageal reflux disease in Japan. J Gastroenterol. 2011;46:1092–1103.
2. Fock KM, Poh CH. Gastroesophageal reflux disease. J Gastroenterol. 2010;45:808–815.
3. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD)–acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537–545.
4. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004;2:656–664.
5. Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273–1283.
6. Drewes AM, Reddy H, Pedersen J, et al. Multimodal pain stimulations in patients with grade B oesophagitis. Gut. 2006;55:926–932.
7. Koek GH, Tack J, Sifrim D, et al. The role of acid and duodenal gastroesophageal reflux in symptomatic GERD. Am J Gastroenterol. 2001;96:2033–2040.
8. Tack J, Koek G, Demedts I, et al. Gastroesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? Am J Gastroenterol. 2004;99:981–988.
9. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut. 1995;37:7–12.
10. Everaerts W, Nilius B, Owsianik G. The vanilloid transient receptor potential channel TRPV4: From structure to disease. Prog Biophys Mol Biol. 2010;103:2–17.
11. Mihara H, Boudaka A, Sugiyama T, et al. Transient receptor potential vanilloid 4 (TRPV4)-dependent calcium influx and ATP release in mouse oesophageal keratinocytes. J Physiol. 2011;589:3471–3482.
12. Zagorodnyuk VP, Chen BN, Costa M, et al. Mechanotransduction by intraganglionic laminar endings of vagal tension receptors in the guinea-pig oesophagus. J Physiol. 2003;553:575–587.
13. Bielefeldt K, Davis BM. Differential effects of ASIC3 and TRPV1 deletion on gastroesophageal sensation in mice. Am J Physiol Gastrointest Liver Physiol. 2008;294:G130–G138.
14. Krarup AL, Ny L, Astrand M, et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther. 2011;33:1113–1122.
15. Everaerts W, Zhen X, Ghosh D, et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci USA. 2010;107:19084–19089.
16. Fichna J, Mokrowiecka A, Cygankiewicz AI, et al. Transient receptor potential vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment? Neurogastroenterol Motil. 2012;24:e557–e560.
17. Ramachandran R, Noorbakhsh F, Defea K, et al. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov. 2012;11:69–86.
18. Kandulski A, Wex T, Monkemuller K, et al. Proteinase-activated receptor-2 in the pathogenesis of gastroesophageal reflux disease. Am J Gastroenterol. 2010;105:1934–1943.
19. Fan HC, Zhang X, McNaughton PA. Activation of the TRPV4 ion channel is enhanced by phosphorylation. J Biol Chem. 2009;284:27884–27891.
20. Grant AD, Cottrell GS, Amadesi S, et al. Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. J Physiol. 2007;578:715–733.
21. Kono K, Takahashi A, Sugai H, et al. Oral trypsin inhibitor can improve reflux esophagitis after distal gastrectomy concomitant with decreased trypsin activity. Am J Surg. 2005;190:412–417.
22. Mizuno A, Matsumoto N, Imai M, et al. Impaired osmotic sensation in mice lacking TRPV4. Am J Physiol Cell Physiol. 2003;285:C96–C101.
23. Kawao N, Nagataki M, Nagasawa K, et al. Signal transduction for proteinase-activated receptor-2-triggered prostaglandin E2 formation in human lung epithelial cells. J Pharmacol Exp Ther. 2005;315:576–589.
24. Miwa H, Kondo T, Oshima T, et al. Esophageal sensation and esophageal hypersensitivity—overview from bench to bedside. J Neurogastroenterol Motil. 2010;16:353–362.
25. Farre R. Pathophysiology of gastro-esophageal reflux disease: a role for mucosa integrity? Neurogastroenterol Motil. 2013;25:783–799.
26. Yoshida N, Kuroda M, Suzuki T, et al. Role of nociceptors/neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease. Dig Dis Sci. 2013;58:2237–2243. doi:10.1007/s10620-012-2337-7.
27. Yu S, Undem BJ, Kollarik M. Vagal afferent nerves with nociceptive properties in guinea-pig oesophagus. J Physiol. 2005;563:831–842.
28. 2+ in human esophageal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2011;301:G138–G147.
29. Weijenborg PW, Bredenoord AJ. How reflux causes symptoms: reflux perception in gastroesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2013;27:353–364.
30. Page AJ, O’Donnell TA, Blackshaw LA. P2X purinoceptor-induced sensitization of ferret vagal mechanoreceptors in oesophageal inflammation. J Physiol. 2000;523:403–411.
31. McIlwrath SL, Davis BM, Bielefeldt K. Deletion of P2X3 receptors blunts gastro-oesophageal sensation in mice. Neurogastroenterol Motil. 2009;21:e66–e890.
32. Banerjee B, Medda BK, Schmidt J, et al. Altered expression of P2X3 in vagal and spinal afferents following esophagitis in rats. Histochem Cell Biol. 2009;132:585–597.
33. Suzuki M, Mizuno A, Kodaira K, et al. Impaired pressure sensation in mice lacking TRPV4. J Biol Chem. 2003;278:22664–22668.
34. 2+ influx in mouse esophageal epithelial cells. Neurogastroenterol Motil. 2011;23:1020–1028.
35. Awayda MS, Bengrine A, Tobey NA, et al. Nonselective cation transport in native esophageal epithelia. Am J Physiol Cell Physiol. 2004;287:C395–C402.
36. Yamasaki T, Oshima T, Tomita T, et al. Effect of age and correlation between esophageal visceral chemosensitivity and mechanosensitivity in healthy Japanese subjects. J Gastroenterol. 2013;48:360–365.
37. Thorneloe KS, Cheung M, Bao W, et al. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med. 2012;4:159ra148.
38. Lohman RJ, Cotterell AJ, Suen J, et al. Antagonism of protease-activated receptor 2 protects against experimental colitis. J Pharmacol Exp Ther. 2012;340:256–265.